Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan’s Revised Drug Distribution Guidelines Take Effect
The Ministry of Health, Labor and Welfare (MHLW) on March 1 officially revised its Guidelines for the Improvement of Commercial Transaction Practices of Ethical Drugs. The MHLW issued a notification the same day, announcing the revision and sharing the final…
To read the full story
Related Article
- Re-Priced Unprofitable Products Subject to Unit Price-Based Trades for 2 Years: MHLW
March 12, 2025
- Wholesaler Group Launches Database for Unit Price-Based Negotiations
April 2, 2024
- Ryukaikon OKs Revised Distribution Guidelines, Pharmas Urged to Explain Rationale of Solo Wholesaler Policy
December 22, 2023
- MHLW Proposes Setting Key Drugs as Category Separated from Bundled Trades
September 29, 2023
- Guidelines Should Urge Drug Makers to Explain Solo-Wholesaler Decisions: Panel Members
September 29, 2023
REGULATORY
- MHLW Study Group Proposes Six Options to Put Japan’s Patent Linkage System into Law
July 9, 2026
- Chuikyo Kicks Off Debate on FY2027 Off-Year Drug Price Revision
July 9, 2026
- Boehringer’s Big-Seller Hopeful Jascayd Set for Listing, Haihe’s Haizexin Too
July 9, 2026
- Chuikyo OKs NHI Listing for Ferring’s Adstiladrin, Ishin’s Allostem Sheet
July 9, 2026
- JPA’s Watanabe Joins Chuikyo as Healthcare Provider Rep
July 9, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…